Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal P. S. Raghav et al. · The Lancet Oncology · 2021

Cited by 422 works. doi:10.1016/s1470-2045(21)00086-3

Authors

References